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ABSTRACT  (ENGLISH)  
Neuroblastoma (NB) is a pediatric cancer arising from the neural crest cells forming the 
sympathetic nervous system. Just as other types of pediatric cancer the driving mutations of 
neuroblastoma are few and the tumors are instead categorized according to genetic 
abbreviations such as amplification, loss of heterozygosity, gains and translocations. 
Neuroblastoma continues to be therapeutically challenging and flabbergasts scientists and 
doctors with it vast heterogeneity both clinically and biologically. The tumors range from 
aggressive, fast growing, lethal cancer to metastatic tumors that will spontaneously regress 
and disappear without any clinical interventions. The survivors of high-risk neuroblastoma 
struggle with life-long side effects due to the aggressive therapeutic treatment used in these 
young children. In this thesis I have focused on discovering alternative mechanisms that can 
contribute to the development and malignancy of neuroblastoma.  
Paper I.	  High-risk neuroblastoma has been shown to have high level of DNA methylation of 
putative tumor suppressors. We designed a therapeutic strategy where we exploited the 
reversibility of DNA methylation and combined the DNA-demethylating drug 5-Aza-
deoxycytidine (AZA) with the differentiation-promoting activity of retinoic acid (RA) as an 
alternative strategy to treat high-risk neuroblastoma. In this paper we showed that treatment 
with AZA restores high-risk neuroblastomas sensitivity to RA. Additionally, the combined 
systemic distribution of AZA and RA impedes tumor growth and prolongs survival in vivo. 
Genomewide analysis of treated tumors revealed that the combined treatment induced a 
HIF2α-associated hypoxia-like transcriptional response followed by an increase in neuronal 
gene expression and a decrease in cell-cycle gene expression. We performed a loss-of-
function experiment using a small-molecule inhibitor of HIF2α which resulted in diminished 
tumor response to AZA+RA treatment. Our study indicated that the increase in HIF2α levels 
is a key component in the tumor response to AZA+RA and that high levels of HIF2α, but not 
HIF1α, significantly correlate with expression of neuronal differentiation genes and better 
prognosis, but negatively correlate with key features of high-risk tumors. Contrary to 
previous studies, our findings indicate an unanticipated tumor suppressive role for HIF2α in 
neuroblastoma. 
Paper II. We explored the role of hypoxia inducible transcription factor EPAS1/HIF2α in 
neuroblastoma. We analyzed several neuroblastoma tumor expression datasets which showed 
that EPAS1 expression is associated with better patient outcome and characteristics of low-
risk tumors and did not support an oncogenic role as previously shown in other studies. We 
continued by treating xenografted mice with HIF2α inhibitors, which did not block in vitro 
neuroblastoma cell proliferation nor tumor growth. To illuminate the role of EPAS1 during 
embryonic development we analyzed single cell data sets from the developing mouse 
sympathoadrenal lineage, wherein expression of Epas1 was a strong predictor of the most 
differentiated cells and negatively correlated with key progenitor characteristics. 
Additionally, the genes co-expressed with Epas1 in the sympathoadrenal lineage were 
associated favorable patient outcome and features of low-risk neuroblastoma. 
  
Paper III. Due to the lack of recurrent mutations in neuroblastoma it has become more 
important to focus on alternative mechanisms that can influence the development of pediatric 
cancers. We have studied the role of fusion transcripts and proteins in neuroblastoma to 
illuminate possible oncogenic properties. Utilizing sequenced neuroblastoma datasets we 
have been able to identify neuroblastoma specific fusion transcripts. We could identify 
enrichments of fusions in regions frequently gained or lost in high-risk neuroblastoma as well 
as fusions of well-known drivers of neuroblastoma. To explore potential oncogenic properties 
of fusion proteins we focused on the ZNF451-BAG2 fusion which generates a truncated 
BAG2 protein, that we call ΔBAG2. When overexpressing ΔBAG2 in neuroblastoma cell 
lines we see impaired retinoic acid-induced differentiation. Indicating that ΔBAG2 could play 
a role in neuronal maturation, potentially leading to a less differentiated and more aggressive 
tumor. Our findings reveal an overlooked mechanism capable of generating altered gene 
products, which are relevant for neuroblastoma pathogenesis and presents new potential drug 
targets. 
  
  
ABSTRAKT  (SVENSKA)  
Neuroblastom är en pediatrisk cancer som drabbar spädbarn och små barn. Ungefär 20 barn 
insjuknar per år i neuroblastom i Sverige och är den vanligaste cancern hos barn under ett år. 
Neuroblastom är en cancertyp som tros uppkomma tidigt under utvecklingen, i celler som 
utvecklas till nervceller som bildar det sympatiska nervsystemet. Barn med neuroblastom 
utvecklar tumörer längst ryggraden eller i bukhålan. Vanligaste stället att få neuroblastom på 
är i binjuren som är placerad strax ovanför njuren.  
Neuroblastom är en intressant cancertyp då den skiljer sig mycket från fall till fall både 
biologiskt och kliniskt. Barn under 18 månaders ålder får ofta en mer lättbehandlad variant av 
neuroblastom medan äldre barn över 18 månader ofta får en variant som kräver intensivare 
behandling och som kan vara svårare att bli av med. Dock så finns det en variant som drabbar 
de allra minsta barnen som ofta redan har bildat metastaser tidigt men som förvånansvärt nog 
kan växa bort av sig själv utan någon klinisk behandling. 
Till skillnad från cancertyper som drabbar vuxna, har barncancer ofta väldigt får mutationer. 
Det vill säga fel som uppstår i DNA-koden som reglerar och kontrollerar alla våra celler i 
kroppen. Eftersom man har hittat så få mutationer i neuroblastom, använder man sig istället 
av genetiska förändringar som skett i tumören för att dela in patienterna i olika subgrupper. 
Dessa genetiska förändringar är till exempel extra kopior av gener (en del av DNA som bildar 
ett protein), extra delar eller hela kromosomer (de strukturer som DNA är uppdelat i), att det 
saknas delar av andra kromosomer eller att en liten del av en kromosom sitter på fel ställe.  
Prognosen varierar beroende på vilken ålder barnet är i då det diagnostiseras, om tumören är 
på ett ställe eller har spridit sig (bildat metastaser) och egenskaper hos den enskilda tumören 
(genetiska förändringar). Överlevnad hos barn med neuroblastom har ökat från under 20 
procent i början av 1990-talet till drygt 60 procent i mitten av 2000-talet. Dock så definieras 
ungefär hälften som högriskpatienter med hög sannolikhet för återfall och död trots 
kombinationsbehandling, så det finns fortfarande ett stort behov av att förstå neuroblastom 
bättre och utveckla nya behandlingsmetoder.  
Högrisk-neuroblastom som är svår att operera och som har spridit sig till olika delar av 
kroppen behandlas med höga doser cytostatika (cellgifter) och operation samt i kombination 
med stamcellstransplantation. Därefter följer strålning och slutligen behandling med A-
vitamin. De barn som överlever den aggressiva formen får ofta komplikationer till följd av 
den tuffa behandlingen och kan leda till besvär som t.ex. hörselnedsättning, njurskador, 
hormonrubbningar, infertilitet, neurologiska och psykologiska förändringar samt risk för 
sekundär cancer. 
I denna avhandling har vi fokuserat på att hitta alternativa mekanismer som kan hjälpa till att 
förklara uppkomsten av neuroblastom och utifrån det har vi designa nya behandlingsmetoder 
som vi hoppas kan förbättra överlevnaden och livskvalitén hos barn som drabbas av 
neuroblastom. 
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1   INTRODUCTION  
1.1   Cancer  
Cancer is not one disease it is a collection of related diseases defined by uncontrolled cell 
proliferation in a tissue. Caused by changes that alter gene expression and provide a growth 
benefit in cancer cells compared to normal cells. These changes can be caused by many 
different factors; mutagenic, viruses, epigenetics, stress, radiation or simply age [1, 2].  
Cancer is caused by dynamic changes in the genome often by mutations producing oncogenes 
or alter tumor suppressor genes which transform normal cells in to malignant cancer cells. 
Cancer development is multi-step process in which cells progressively accumulate genetic 
change which may contribute to a growth advantage, similar to Darwinian evolution, and as 
changes accumulate it can dive the development and progression of cancer. For a cancer 
tumor to develop a cell needs to survive, proliferate and often also spread to different parts of 
the body causing metastases [1, 2]. To do so the cell has to elude anti-cancer defense 
mechanisms built in to cells and tissues.  
Mutation frequency vary a lot depending on the type of cancer and the tissue it originates 
from. Pediatric cancers have very low mutation rate (as low as 0.1 mutations/Mb) compared 
to cancer types in the adult. There are also cancers with extremely high mutation rate, such as 
melanoma and lung cancer which can exceed 100 mutations/Mb. Cancers with extremely 
high mutation rate are thought to be due to exposure to well known carcinogens such as UV-
light and tobacco smoke [3]. When looking at a specific cancer type the amount of mutations 
may still vary a lot, this could be due to underlying key biological features. In head and neck 
cancer the tumors can have a viral or non-viral origin which may affect the mutation 
frequency [4]. However, the majority of mutations are “passenger” mutations rather the 
“drivers” and are in many cancers correlated with age [5].  
 
1.2   Adult  vs  Pediatric  Cancer  
Taken in to account that for a normal cell to become a malignant tumor cell it has to sustain 
proliferative signaling, resist cell death, evade growth suppressor, induce angiogenesis, 
enable replicative immortality and activate invasion and metastasis [1, 2]. It´s not surprising 
that cancer is a disease of the elder, simply because of the time it would take to accumulated 
genetic damage to be able to do all of that. The question remains however; how can a disease 
that takes decades to develop in an adult, become a full blown metastatic cancer in a child 
less then a year of age, as in the pediatric cancer Neuroblastoma?  
While cancer cells and embryonic cells are not identical it is clear that cancer cells have 
retained and/or regained embryonic features which gives a selective advantage contributing to 
cancer development. Due to the early onset in pediatric cancers it may indicate that the first 
oncogenic event happened early in life or already prenatally. Could it be that young children 
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provide an environment that may provide favorable conditions for cancer development? 
Developmental process from a fertilized egg to a complex multicellular organism as humans 
is long and complicated process. Genes have to be turned off and on in a certain order for 
specialized tissues to develop. Once turned of lineage specific genes has to stay off for a cell 
to continue developing in the right track [6]. It is easy to imagine that a mistake can halter a 
cell in an undifferentiated stage and can eventually potentially lead to development of cancer. 
Neuroblastoma has been suggested to develop due to abnormal or complications during 
differentiation. During embryonic, prenatal as well as postnatal development many stem cells 
are still present, cell populations are still expanding and differentiating to give rise to 
specialized tissues. 
Hereditary disease is believed to contribute to around 10% of adult cancers. In neuroblastoma 
it has been estimated that less than 1-2% are familial [7-10] and around 9% overall in 
pediatric cancer [11], suggesting that germ line mutations does not contribute to the 
neuroblastoma cancer evolution. Although it cannot be excluded that these numbers are 
effected by the fertility of childhood cancer survivors [12].  
One of the major differences comparing adult and pediatric/childhood cancer is the 
mutational load. Adult cancer such as colon, brain, pancreas and breast cancer have an 
average of 33-66 somatic mutations causing alterations in protein products. Pediatric and 
liquid (leukemia) cancers harbor on average 9.6 mutations per cancer. Although, if a cancer 
relapse the tumor or metastasis has often acquired new mutations. Cancer caused by 
mutagens (such as lung cancer and melanoma) harbor shockingly 200 mutations per tumor 
[5].  Giving an indication that pediatric cancer is probably not caused by mutagens. The 
involvement of environmental factors during pregnancy is hard to exclude, but there is clearly 
a lower impact of exogenic toxic effect in children then in adults. Smoking, sun exposure, 
overweight and alcohol consumption can be excluded [13]. Certainly, the low number of 
mutations suggests that only a few genetic alterations are required to drive pediatric 
oncogenesis. The lack of driving mutations can be limiting as the mutations may provide 
more possible therapeutic targets, making pediatric cancer a therapeutic challenge.   
In certain tumors in self-renewing tissue the number of mutations are directly correlated with 
age [14]. Additionally, more than half of the somatic mutations are often “passenger” 
occurring during, or even before, tumor development. This may be one explanation why 
pediatric cancer has fewer mutations, since pediatric cancer often is thought to arise from 
non-renewing tissues, which hasn’t had time to accumulate as many mutations [5].  
 
1.3   Neuroblastoma  
Neuroblastoma (NB) is the most common extra cranial solid tumor in children and the most 
frequently diagnosed neoplasm in infants. NB accounts for around 10% of all childhood 
cancers [15, 16]. Unproportionally, NB accounts for around 15% of all oncologic deaths in 
children under 15 years of age. NB is a pediatric cancer thought to arising in the neural crest 
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cells of the sympathoadrenal lineage and tumors can form anywhere in the sympathetic 
nervous system. Most commonly as an abdominal mass in the adrenal medulla (around 50%) 
or in the para spinal ganglia, posterior mediastinum, pelvis and neck. Around half of the NB 
are metastatic and metastatic sites often include bone marrow, cortical bone, liver and lymph 
nodes [15, 17, 18]. 
Neuroblastoma is a fascinating disease with immense heterogeneity both biologically and 
clinically. Ranging from fast growth tumors with poor patient survival to being one of the 
cancers with the highest reported cases of spontaneous regression without any clinical 
intervention [19, 20]. Like other pediatric cancers NB harbors few somatic mutations and is 
instead characterized by genomic changes identified, which allows tumors to be divided into 
subgroups. Even though a lot of progress has been made in understanding the pathogenesis 
behind NB as well as developmental biology of the sympathetic nervous system, NB remains 
a therapeutically challenge. The prognosis of high-risk NB is still bad and the patients that 
survive treatment are left with life long side effects.   
The mean age at diagnosis of familial NB is 9 month compared to the mean age of 18 months 
in the general population. About 40% of children with NB are diagnosed before one year of 
age, 75% before 4 years and 98% before they reach 10 years [10]. Neuroblastoma detection 
in early life or in utero suggests that early disruption of normal developmental processes may 
play a part in tumor initiation. 
Staging of NB is important to be able to select the right course of treatment. Age, histology, 
DNA ploidy, MYCN amplification, chromosomal changes, neurotropin receptors and 
metastatic status, is taken into account when staging NB.  NB is classified using two different 
systems; one pre-surgical risk classification system which is based on image tests usually CT 
or MRI and is classified into four groups International Neuroblastoma Risk Group 
(INRG)[21] or post-surgical International Neuroblastoma Staging System (INSS)[22]. 
Table 1. Summary of staging systems for neuroblastoma 
INRG staging system INSS 
L1: Localized tumor, not involving vital structures 
and confined to one body compartment 
L2: Locoregional tumor with presence of one or 
more image-defined risk factors 
M: Distant metastatic disease 
MS: Metastatic disease in children younger than 
18 months with metastases confirmed to skin, liver 
and/or bone marrow 
Stage 1: Low risk, no MYCN amplification, localized 
tumor that can be removed by surgery.  
Stage 2: Relative low risk, no MYCN amplification, 
localized tumor, tumor cells may have some spread to local 
lymph nodes.  
Stage 3: Intermediate risk, unable to resect the full tumor 
during surgery, tumor extending beyond the midline and 
lymph node involvement.  
Stage 4: High risk, can have MYCN amplification, older 
age at diagnosis and metastatic disease.  
Stage S4: Spontaneous regression, tumors that appear 
metastatic but undergo regression without the intervention 
of therapies.   
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Histopathologically are NB undifferentiated with lots of small round cells (neuroblasts).  The 
tumors are classified as favorable or unfavorable depending on the degree of neuroblast 
differentiation, Schwannian and stroma content, mitosis-karyorrhexis index and age at 
diagnosis [23]. 
What is the biological explanation for metastatic tumors that spontaneously regress and 
disappear? Could that information benefit the children with high-risk NB or are the high-risk 
tumors different? Tumors stage 4s (s=special) occur in young children which gets small 
localized primary tumors, although highly metastatic, but with a unique pattern of metastasis 
mainly in the liver and skin. The tumors will regress and disappear without any or little 
clinical intervention [24]. Infants under 1 year of age are at risk for both anesthetic and 
surgical complications associated with resection of adrenal tumors [25] and should not be 
subjected to surgery if not necessary. A study showed that 80% of patients where an adrenal 
mass was detected during the perinatal period, who did not get surgical intervention had 
100% survival [26]. The exact mechanism through which NB tumors spontaneously regress 
and differentiate is still unclear, several alternatives have been suggested; delayed activation 
of developmentally programmed cell death by neurotrophin, epigenetic regulation and loss of 
telomerase activity. 
Screening studies in Japan, Europe and Canada have been performed measuring tumor-
derived catecholamines in urine samples of six month infants. The incidence of NB in the 
screened population was substantially increased (1:2000 vs 1:7000) but the NB had favorable 
biological features and did not improve survival, resulting in the termination of screening 
studies worldwide [27, 28]. The increased prevalence of NB in the screening studies indicates 
that spontaneous regression occurs at least as frequently as NB detected clinically. 
Additionally, this indicated that favorable tumors rarely evolve into biologically unfavorable 
NB tumors and neuroblastoma tumors likely have established features of either low- or high-
risk disease at the time of disease onset. 
NB is a hard disease to treat without causing excessive harm. Due to the young age of the 
patients, treatment with chemotherapy will affect many cell types and tissues. Treatment 
strategies depend on risk stratification and treatment range from observation (only), surgery 
and/or chemotherapy to high-risk NB high-dose chemotherapy, surgery, autologous stem cell 
transplantation, radiotherapy, immunotherapy and differentiation therapy (with Retinoic 
acid).  Treatment with retinoids have shown to increase event free survival (EFS) in high risk 
NB after chemotherapy and autologous stem cell transplantation [29]. Survivors of aggressive 
muli-modal therapy face long-term consequences such as poor growth, hearing loss, 
developmental, renal and lung impairment, endocrine disturbances, neurological deficits and 
secondary cancers [30].  
Retinoic acid (RA) is a vitamin A metabolite, which has been shown to be important during 
embryonic development for organogenesis, the development of the sympathetic nervous 
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system and can differentiate neuronal cells in vitro [31]. RA regulation of specific target 
genes goes through the retinoic acid receptors (RARs), which functions as a ligand-dependent 
transcription factor. RARs forms heterodimers with retinoid X receptors (RXRs) and bind to 
retinoic acid response elements (RAREs) in the promoter region of target genes. In absence 
of a ligand it actively represses transcription together with co-repressors [32]. Treatment with 
all-trans-retinoic acid (tretinoin) and 13-cis-retinoic acid (isotretinoin) has been used in a 
randomized control study to treat high risk neuroblastoma in combination with 
myeloablastive chemotherapy, total body irradiation and transplanted autologous bone 
marrow and improved treatment outcome [29].  
Neuroblastoma is thought to originate in neural crest derived cells, where defects in neural 
crest cell migration, maturation or differentiation might contribute to neuroblastoma 
development. Neural crest cells (NCCs) are a transient collection of multipotent embryogenic 
progenitors, which arise between the neuroepithelium and the developing epidermis and can 
give rise to a variety of cells. The neural crest cells develop from the ectoderm, specifically 
between the neural plate and the epidermis at the neural plate border. During neurulation the 
neural plate invaginates at the dorsal midline and create a neural grove, the neural folds will 
eventually meet and fuse, creating the neural tube. The neural crest is located on the dorsal tip 
of the neural tube. To be able to migrate the cells undergo epithelial to mesenchymal 
transition (EMT). The cells that will form the sympathoadrenal lineage will migrate out 
around the neuronal tube to the region laterally to the notochord and the dorsal aorta. The 
NCCs migrate extensively during embryogenesis and give rise to a vast variety of cells; the 
peripheral nervous system, the enteric nervous system, melanocytes, Schwann cells, adrenal 
medullary cells and cells of the craniofacial skeleton [33].  
Postsynaptic neuroendocrine chromaffin cells are located in the adrenal medulla and produce 
catecholeamines which are released into the blood stream, where they effect stress response 
and metabolism. A recent study by the Adameyko lab looking at the cellular origin and 
development of the adrenal medulla, show that a large number of chromaffin cells actually 
arise from Schwann cell precursors (SCPs). The study shows that NCCs split into two 
lineages after the first migration, one which will from the sympathetic neurons and one 
lineage that will from SCPs, which in turn will later form the chromaffin cells of the adrenal 
medulla [34].  
 
1.4   Alterations  in  Neuroblastoma  
Although some patients with Neuroblastoma have predisposition to the disease, most NB 
occur spontaneously. Activating mutations of anaplastic lymphoma kinase (ALK) are one of 
the few hereditary mutations which predispose to neuroblastoma [7]. A single-base 
substitution in the ALK gene causes a constitutive activation of the receptor tyrosine kinase 
[7, 35]. ALK alterations occurs both as gene-activating mutations and gene amplification. 
Around 10% of sporadic neuroblastoma have an ALK activating mutation and additionally 
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5% of neuroblastoma has ALK amplification, both which is associated with poor prognosis 
[35, 36]. ALK has been shown to protect against in utero nutrition deprivation during the 
neuroblast growth in early sympathoadrenal development. Knockdown of ALK lead to a 
decrease of proliferation [35]. ALK is involved in the regulation of MYCN transcription and 
is suggested to work synergistically in neuroblastoma to drive tumor development [37, 38]. 
ALK stimulates the transcription of a number of genes for example HIF1/2, VEGF, NFkb 
and SHH [39].  
The 1-2% of NB which is familial, two genes have been identified ALK and PHOX2B 
accounting for 80% of hereditary NB. Inactivating mutation of PHOX2B accounts for 5% of 
these. PHOX2B is expressed in NCCs and is required for normal development of the 
sympathetic ganglia and aberrations can have varying effects on differentiation [40, 41].  
Amplifications of genes are common in many types of cancer and often occur in oncogenes. 
In NB the amplification of MYCN, which occurs in around 20% of NB tumors, is strongly 
correlated with poor out come and strongly correlated with worse prognosis, aggressive 
tumors and decreased overall survival [42]. MYCN is normally located at the short arm for 
chromosome 2 and when expressed form a heterodimer together with MAX. Together they 
acts as a transcriptional activator promoting to cell cycle progression [43, 44]. MYCN is 
highly expressed in early post-migratory neural crest cells during normal sympathoadrenal 
development, regulating the ventral migration and expanding neural crest population. MYCN 
levels are gradually reduced as the cell differentiate into sympathetic neurons [45]. High 
levels of MYCN reactivates cell cycle and prevents cell death caused by NGF withdrawal in 
rats [46, 47]. In zebrafish overexpression of MYCN blocks chromaffin cell differentiation 
and causes hyperplasia in adrenal sympathetic neuroblast [38]. MYCN overexpression in 
transgenic mice forms neuroblastoma tumors [48], however the effect varies depending on 
genetic background. 
Large chromosomal rearrangement is a common feature in many types of cancers. When a 
large part of the chromosome is duplicated or deleted it is hard to identify specific genes that 
are important for pathogenesis. Homozygous deletion often involves just a few genes and 
targets tumor suppressor genes. Deletion in one of the homologous chromosomes resulting in 
a loss of heterozygosity (LOH) and is a common feature in NB. One of the most common 
LOH occurs in the short arm of chromosome 1 (1p). The smallest region, the 1p36 locus is 
lost in around 35% of the NB and is often correlated with advanced disease stage and MYCN 
amplification. The gene or genes located at the 1p36 locus responsible for the pathogenesis is 
not yet clear. Several genes have been proposed to be the 1p36-encoded tumor suppressor. 
CHD5 is a chromatin remodeler involved in neuronal differentiation, suggested to have tumor 
suppressive properties [49-52]. KIF1Bß, another gene located at the 1p36 locus is involved in 
developmental apoptosis and mutation have shown to impaired apoptosis in sympathetic 
neurons during developmental culling [53, 54]. However, no bona fide tumors suppressor 
function has yet to be defined at the 1p36 locus and so the quest to find the 1p36 tumor 
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suppressor continues [55]. Although it cannot be excluded that the collective loss of genes in 
this region contributes to the pathogenies of NB.    
Another region exhibiting LOH is the long arm of chromosome 11 (11q), deletion of 11q23 
are found in around 40% of NB tumors, making it the most common deletion in NB. 
Interestingly it is inversely associated with MYCN amplification, but still remains correlated 
with high-risk features. LOH of 11q is associated with decreased event-free survival, but only 
in patients lacking MYCN amplification [56].  
High expression of TrkA is a favorable indicator, thought to mediated apoptosis or 
differentiation. High expression levels of TrkA are correlated with young age, absence of 
MYCN and low grade tumors [57]. Conversely, high expression of TrkB is associated with 
bad prognosis particularly in those harboring MYCN amplifications [58].  
Trisomy of chromosome 17 or gain of the long arm (17q) occurs in more than half of 
neuroblastoma and is therefore the most prevalent genetic abnormality identified in NB [59-
61]. Survivin, an inhibitor of apoptosis has been suggested as the gene located in this region 
providing a survival benefit [62]. The partial gain of 17q due to unbalanced translocation is 
associated with 1p- and MYCN+ and worse prognosis. The common site for translocation of 
17q gain is to chromosome 1 (1p) [60].  
When looking at the karyotypes of tumors in NB patients; polyploidy (often close to triploid) 
is associated with less aggressive NB and is thought to be due to defects in mitosis causing 
the whole chromosome gains or losses. Diploid has worse prognosis in patients younger than 
18 months with metastatic disease [63]. After 2 years of age the karyotype loses its 
prognostic significance, this is thought to be due to the hole chromosome gain without 
structural rearrangements in infants and after 2 years the hyperploidy is associated with 
possible oncogenic rearrangements [16, 64].  
MicroRNA has been shown to play an important regulatory role in cells, targeting mRNA for 
degradation or translation repression. Additionally, several preclinical and clinical trials have 
been initiated for microRNA-based therapeutics [65]. LIN28B is an RNA binding protein 
which regulates the expression of let-7 (microRNA) family and is expressed in developing 
tissues and stem cells, but gets down regulated during differentiation [66]. LIN28B inhibits 
let-7 and has been shown to promote a pluripotent state [67]. During embryonic development 
LIN28B is expressed in the neural tube and regulates developmental timing and cellular 
growth during neural crest cell lineage commitment [67]. High expression of LIN28B 
elevates the expression of MYCN and is associated with worse neuroblastoma prognosis. 
Targeted overexpression of LIN28B in the neural crest can cause the development of 
neuroblastoma [68].  
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1.5   Epigenetic  Modifications  
Epigenetic modifications to DNA are heritable genomic modifications that does not change 
the DNA sequence but can regulate gene expression through DNA and histone methylation 
and acetylation that influence chromatin structure. Epigenetic regulation of gene expression is 
critical for both normal development and to maintain tissue-specific expression [69]. Because 
of the low mutation load found in NB, scientists have looked at alternative mechanisms such 
as DNA methylation that have the potential to inactivate tumor suppressors, in the hope of 
finding more information about the mechanisms effecting and contributing to neuroblastoma. 
Several studies have looked at DNA methylation in neuroblastoma [70-72] and found several 
important genes with hypermethylated promoter regions, such as CASP8 [73] and 
RASSF1A[74]. 
Epigenetic changes can be inherited through cell divisions and has been suggested as an 
alternative or additive mechanism to mutations and genetic alterations, in the way of 
changing gene expression and driving tumor evolution [2]. It has been discovered that the 
epigenetic landscape is different in cancer versus normal tissue in a variety of cancer [75, 76] 
and changes were found even in benign and pre-malignant tumors [77, 78]. Several cancer 
show global hypomethylation and gene promoter hypermethylation [75]. Global 
hypomethylation is associated with genomic instability [79], loss of imprinting [80] and 
shows a higher frequency of unbalanced chromosomal translocation causing LOH [76, 81]. 
Promoter hypermethylation as a way to silence tumor suppressors, has been suggested as a 
potential therapeutic target. 
Epigenetics is thought to be important in generating different phenotypes from identical 
genotypes. Such as in monozygotic twins which have identical genotype but differ in their 
epigenetic phenotype [82, 83]. Several diseases have been suggested to develop when the 
wrong type of epigenetic marks are introduced or are added at the wrong time or at the wrong 
place. Epigenetic modifications is a non-mutational ways to effect gene regulation which can 
contribute to genome instability  in cancer [2]. 
Drugs targeting epigenetic modifications have been used as therapy in different cancers. 5-
aza-2´deoxycytidine (AZA) is a cytosine analogue which takes the place of the cytosine 
during DNA replication and prevents DNA methylation by DNA methyltransferease1 
(DNMT1) [84]. Treatment with AZA seek to remove methylation and activate genes which 
have been aberrantly turned off. In cancer for example the hope is to reactivate tumor 
suppressor genes that have been silenced [84]. There have been studies similar to ours (Paper 
I.) were the synergy of retinoid with epigenetic modifiers have been efficient in reducing 
tumors growth [85, 86].  
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1.6   Hypoxia    
Most organisms such as yeast, bacteria, invertebrates and vertebrates require oxygen for 
survival. Even small changes in oxygen levels can be harmful. However low oxygen 
(hypoxia) occurs naturally during embryonic development where it coordinates important 
developmental processes such as the development of blood, placenta, vasculature and the 
nervous system [87].  During embryonic development the formation of new vasculature is 
crucial for the developing organism. For new blood vessels to form epithelial cells proliferate 
and assembly into hollow tubes (vasculogenesis) as well as sprouting (angiogenesis) form 
already existing ones. After development there is little new formation of blood vessels and 
the vasculature become mostly quiescent, with exception of wound healing and during the 
female reproductive cycling [88, 89]. However, fast proliferation in a cancer creates a greater 
need for oxygen and nutrients as well as a way to remove metabolic waste and carbon dioxide 
causing a hypoxic environment.  Many cancers induce angiogenesis by expressing pro-
angiogenetic factors such as VEGF-A. VEGF-A are involved in the organization of new 
blood vessels during embryonic and postnatal development and survival and endothelial cells. 
The vasculature in tumors are frequently dysfunctional with leakage, extensive branching and 
bad flow, probably due to chronic expression of angiogenic factors [87, 90]. 
Physiological (normoxic) oxygen levels in the human body vary widely (2-9% O2) depending 
on the organ. Some organs such as the thymus, kidney medulla and bone marrow can have as 
low as 1% O2. Hypoxia is often associated with pathologies such as inflammation, ischemia 
and cancers with solid tumors. During embryonic development, the first weeks after 
fertalization before a circulatory system is established, mammalian development occurs in a 
relatively low oxygen environment (1-2% O2) [91]. O2 levels affect placenta development 
and generation of an utero–placental circulation. As the connection with the maternal 
vasculature is established the O2 levels in the placenta increase to around 8% O2 [87]. It can 
be concluded that at least part of the peripheral nervous system development occurs during 
hypoxic conditions.  
Physiological hypoxia during embryonic development encountered in utero has been shown 
to be essential for many developmental processes, for example generating the components of 
the cardiovascular–pulmonary system [87], the development of the neural fold [92], earlier 
steps in bone formation [93], promoting sympathoadrenal differentiation of NNCs [94]. It is 
clear that O2 influences specific cell fates in several developmental processes and can 
modulate cell fate acquisition in a concentration-dependent manner. Therefore, maybe 
oxygen concentration can potentially be considered a developmental morphogen, since it 
influences cell fate in a manner that is similar to for example secreted growth factors.  
The atmospheric oxygen (ambient air) that we breathe has an oxygen concentration of 21% 
O2. Culturing of cells in different oxygen conditions will have different effects on the cells. In 
adult humans, stem cells occupy regions with different oxygen concentration. Hematopoietic 
stem cells reside in the bone marrow where the oxygen concentration is low, other stem cells 
like spermatogonial stem cells reside in more vascularized areas. Raising the question of how 
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we should culture our cells in vitro; in ambient air or rather at physiological conditions for 
our experiments to be more clinically relevant? Growing hematopoietic stem cells at 1,5% O2 
instead of in ambient air has shown to promote engraftment and repopularization of the bone 
marrow [95]. Embryonic stem (ES) cells has been shown to grow more efficiently in lower 
oxygen conditions and are required to maintain the full pluripotency of mammalian ES cells. 
ES cells cultured in ambient air differentiate and lose expression of stem cell markers such as 
OCT-4 [96]. 
Angiogenesis plays an important role in tumor progression and metastasis formation. 
Disturbance of the balance of pro-angiogenic and anti-angiogenic factors in cancer is called 
“the angiogenic switch”. Normal endothelial cells of the blood vessels divide every ten years, 
but tumor endothelial cells can divide as often as every 7-10 days [97]. In cancer some areas 
of the tumor may be completely deprived of oxygen (anoxia) resulting in necrotic regions. 
Hypoxia is involved in resistance to radiation and chemotherapy. Hypoxia inducible factors 
(HIFs) acts as a survival factor by inducing transcription of genes involved in angiogenesis, 
glycolytic metabolism, oxygen consumption and migration [98]. Tumor hypoxia is often 
associated with poor prognosis, resistance to radio- and chemotherapy, but the question 
remains if hypoxia simply is a secondary effect of a fast growing tissue or is it a causative 
effect that contributed to the malignancy?  
Several preclinical and clinical studies have targeted angiogenesis as a therapeutic strategy. 
By blocking the formation of new blood vessels using anti-VEGF drugs and restricting the 
tumors access to oxygen and nutrients, as well as increasing the hypoxia in tumors. The 
treatment with anti-VEGF succeeds in suppressing the formation of new blood vessels, 
however, some hypoxic cancer cells have shown to instead become more invasive and 
metastatic [97, 99-101]. Treatment with anti-angiogenic therapy of human glioblastoma 
showed benefit in treating the primary tumor but caused increased invasion and local 
metastasis formation [90, 102, 103]. This raises concerns about targeting hypoxia and 
angiogenesis as a potential therapeutic target in cancer. Antiangiogenic agents have shown 
promising results in renal cell carcinomas where 30-40% has shown improved progression 
free survival, however the treatment is associated with vast side effects [104]. In other 
cancers the agents have shown efficiency in combination with chemotherapy, but is used 
minutely because of the lack of knowledge on how tumor cells escape the antiangiogenic 
therapy.  
This taken together raises the question whether hypoxia simply is a secondary effect of a 
tissue with uncontrolled proliferation and underdeveloped vasculature. If so could this be the 
reason why there are so many contradicting studies when it comes to the oncogenic or tumor 
suppressive role of HIFs. Or if hypoxia is a primary cause and part of the pathogenesis and 
drives (or at least contributing) to the cancer development and progression? Whether targeted 
therapy to block the vascularization, hence increase the hypoxia would be of therapeutic 
value. Several studies have suggested treatment with HIF2α antagonists in cancer and several 
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clinical trials are ongoing [105-108]. Thirdly, if the hypoxia response isn’t driving the cancer 
would blockage of HIFs be beneficial as a treatment?  
 
1.7   HIF2α    
The hypoxia inducible factors (HIFs) are transcription factors that mediate the primary 
transcriptional response to hypoxic conditions both in normal and transformed cells. There 
are three different HIFα:s identified; HIF1α, HIF2α (encoded by EPAS1) and HIF3α. The α 
subunit is primarily regulated through post-translational modifications (ubiquitination) 
performed by HIF-specific prolyl-hydroxylases (PHDs) in the presence of O2. In normoxia 
proteasomal degradation is mediated in part by von Hippel-Lindau (VHL) tumor suppressor. 
During hypoxic conditions, the HIFα subunit is instead translocated into the nucleus where it 
forms a heterodimer with a stable HIFß unit (also known as ARNT). Together the complex 
binds to hypoxia response elements (HREs) of about 200 genes, such as VEGF, GLUT and 
EPO, where it activates gene transcription [109]. Oncogenic signaling in cancer cells have 
been shown to increase transcription and/or translation of HIFαs in an oxygen independent 
manner [110]. HIF3α mRNA is differentially spliced producing multiple isoforms that either 
promote or inhibit the activity of HIF complexes. Little is known about the effect of HIF3α in 
tumor progression in hypoxic conditions [111-113]. 
Despite structural similarities, HIF1α and HIF2α have distinct roles during embryonic 
development. HIF1α depletion is embryonically lethal (E9.5-10.5) in transgenic mice and the 
embryos dye due to vascular defects [114-116]. HIF2α depleted mice however survive until 
mid/late gestation or in some cases to birth. Depletion of HIF2α in these pups causes 
impaired vascular remodeling and cardiac function in embryos [117, 118] and caused 
neonatal respiratory distress [119] and multi-organ pathology after birth [120]. Suggesting 
that the two genes regulate overlapping but not identical genes.  
Both HIF1α and HIF2α are expressed in hypoxic tumor regions. However, their role in 
tumorigenesis remains controversial as both have been described as both oncogenes and 
tumors suppressors in a tumor context dependent manner. HIF1α has been suggested to be 
involved in the early stages of cancer while HIF2α in the late stages and chronic rather than 
acute hypoxia [121]. High expression of HIF1α in biopsies of brain, breast, cervical, 
esophageal, oropharyngeal and ovarian cancers is correlated with treatment failure, mortality 
and promotes tumor progression [122]. In renal cell carcinoma HIF2α promotes growth, 
while HIF1α has a tumor suppressive role [123]. In hepatocellular carcinoma [124], 
colorectal cancer [125] and soft tissue sarcomas [126] has HIF2α been shown to act as a 
tumor suppressor. Interestingly, in non-small lung cancer has HIF2α been described both as 
an oncogene [127] and as a tumor suppressor [128]. In glioblastoma the role of HIF2α is not 
clear since there is contradicting studies published, indicating a role as a tumor suppressor 
[129] or as an oncogene [130]. 
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In neuroblastoma several studies have published a correlation between high levels of HIF2α 
and high-risk NB [131-134]. But even in NB there are contradicting studies. In a study by 
Simon and colleagues they show that HIF1α is highly expressed in MYCN amplified NB 
tumors, while HIF2α are high in non-MYCN amplified tumors. Additionally, the study 
shown an interplay between HIF1α and MYCN in NB [135]. The precise role of HIF1α and 
HIF2α in cancer biology still remain a puzzle. 
 
1.8   Fusion  Proteins  
Chimeric RNA can be produced by three different mechanisms: Chromosomal rearrangement 
occurs by translocation, deletion or insertion and can cause the formation of new chimeric 
RNAs. Chromosome translocation in cancer can cause fusion of genes which creates an 
oncogene or inactivates a suppressor gene by truncating it or separate it from its promoter 
[136].  
The second mechanism is cis-splicing, where read-through transcription produces one long 
RNA strand. Transcription usually begins at a transcription start site (TSS), guided by a 
promoter and usually ends at a regulated termination point. Genes are separated by intergenic 
(non-transcribed) regions. Chimeric transcripts can occur when the RNA-polymerase reads 
through the termination point and continues to transcribed the consecutive gene and instead 
stops at the termination point of the downstream gene. The intergenic region of the chimeric 
transcript is spliced out and the two normally adjacent genes merge into one [136].  
Thirdly, trans-splicing when two separate RNA strands are spliced and fused into one RNA 
strand. The RNA can be from two different genes either located on the same chromosome 
separated by coding gene or in two distal parts of the chromosome, or even on two different 
chromosomes [136].  
Additionally, fusions can be either interchromosomal or intrachromosomal. 
Interchromosomal fusions occurs between genes located on different chromosomes. 
Intrachromosomal fusions occurs within the same chromosome. The fusion RNA can have a 
functional role or can be transcribed into a fusion protein with a different role then their 
original proteins [136]. Fusions has been detected in tissues in non-pathological condition 
[137, 138]. 
Fusion RNAs has been linked to several types of cancer and were first discovered in 
leukemia and other hematological diseases, but has since then been found in different types of 
cancer [13]. The BCL-ABL fusion in chronic granulocytic leukemia caused by the 
“Philadelphia chromosome” [139]. In non-small cell lung cancer EML4-ALK fusion was 
detected and targeted for treatment using ALK inhibitor [140, 141]. In prostate cancer a large 
number of tumors harbor the TMPRSS2-ERG fusion [142]. Fusions can be used as 
biomarkers and as potential therapeutic targets.  
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Fusion transcripts has been suggested as alternative oncogenic mechanism particularly in 
pediatric cancer where the mutation load is low and genomic rearrangement are common.  
Fusion genes has been identified in pediatric cancer such as leukemia (113), lymphomas (41), 
brain tumors (4), kidney tumors (4), bone and soft-tissue tumors (37) and liver tumors (1) and 
are associated with varying outcome [13].  
1.9   Summary  
Neuroblastoma is a pediatric cancer generated in the sympathetic nervous system. It carries a 
low mutation load and is instead categorized by genetic abbreviations. The prognosis of 
children with high-risk NB remains poor and those that survive will have long-term side-
effects from the toxic treatment. Many pediatric cancers are suggested to have an embryonic 
origin and NB is thought to originate from cells of the neural crest, however the cell of origin 
is not yet determined. The growth promoting environment, with lots of stem cells and 
expanding cell populations during embryonic development together with small changes in the 
cell might provide favorable conditions for cancer development. Because of the low mutation 
rate alternative mechanism has been explored, such as failure to differentiate due to DNA 
methylation silencing of genes important for neuronal differentiation and fusion transcripts 
caused by genomic translocation, to understand the pathogenesis of NB and find new 
therapeutic targets. 
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2   SCIENTIFIC  AIMS  
The mechanisms driving childhood still remains an unsolved mystery in many ways.  
Mutations are one of the key drivers of cancer, however, pediatric cancers have a much lower 
number of mutations compared to adult cancers. In this thesis we have focused on 
illuminating alternative mechanisms that may be important for the development and 
progression of pediatric cancer neuroblastoma. Neuroblastoma continues to be therapeutically 
challenging and flabbergasts scientists and doctors with it vast heterogeneity. The tumors 
range from aggressive, fast growing, lethal cancer to metastatic tumors that will 
spontaneously regress and disappear without any clinical interventions.   
In paper I. we target high-risk neuroblastoma with a new therapeutic strategy. We used a 
combination treatment with the epigenetic drug AZA and the neuronal promoting drug RA, 
to inhibit tumor growth by inducing neuronal differentiation.  
In paper II we continue working with the findings from paper I and explore the role of 
EPAS1/HIF2α in neuroblastoma and evaluate if EPAS1 has a predictive value of clinical 
outcome. We also evaluated the expression pattern of Epas1 in the sympathoadrenal lineage 
during embryonic development.  
In paper III we aimed to identify and characterize fusion transcripts in neuroblastoma.  
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3   RESULTS    
3.1   PAPER  I.    
High levels of DNA methylation of the promoter region of potential tumor suppressor genes 
has been suggested as predictive factor of poor prognosis in Neuroblastoma [72, 143-145]. 
This together with the non-responsiveness of many high-risk NBs to neuronal promoting 
drug RA got us thinking if the failure to differentiate exhibited by high risk neuroblastoma is 
a consequence of the DNA hypermethylation. To do so we investigated whether targeting the 
hypermethylated NB genome with DNA demethylating agents could restore the capacity of 
these cells to respond to differentiation inducing signals and thus counteract tumor growth. In 
particular, we were interested in understanding the role of DNA methylation and its effect on 
tumor development and progression. In addition, we aimed to explore if the hypermethylated 
genome of high risk NB could be exploited as point of entry for treatment of high risk NB 
with demethylating agents. The need for alternative therapeutic strategies in NB are of 
importance. 
Retinoic acid (RA) is a strong promoter of neuronal differentiation and is used as an adjuvant 
treatment in high-risk NB patients, however, with limited effect and low overall survival [29, 
146]. LOH of at the 1p36 locus (1p36-) is a common feature of NB and is associated with 
low event free survival and overall survival [147, 148]. To evaluate the effect of RA on NB 
cells we started by culturing a panel of different cell lines in the presence of RA. Several 
1p36+ (with intact 1p36 locus) NB cell lines responded to RA by changing to a more 
neuronal-like morphology with neurite extension and network formation. Additionally, the 
cells showed upregulated neuronal markers, accompanied with a cessation of proliferation. 
To evaluate the response in vivo we performed a xenograft experiment, where we 
transplanted human NB cells subcutaneously into nude mice. A cohort of the mice was 
subjected to daily i.p. treatment with RA, which results in a distinct reduction of tumor 
growth.  
In our panel of NB cell lines, we found that the more NB cell lines derived from 1p36- 
tumors tend to be unresponsive to RA and continues growing uninhibited in the presence of 
high consentrations of RA. We wondered if the RA resistance could be due to a 
hypermethylated genome. By exploring the reversibility of a hypermethylated genome; we 
decided to combine the demethylating effect of AZA with the neuronal promoting effect of 
RA. Pretreatment with AZA for 4 days in vitro before combining it with RA induced a 
similar response as in the 1p36+ cell lines (to RA alone). Our data indicates that the key to 
the RA responsiveness may lay in the suppression of genes by methylation. However, we 
cannot exclude a possible secondary effect of the AZA treatment, but it is clear that the 
combined treatment is pushing the cells to adopt a more mature neuronal-like phenotype.  
By using a xenograft mouse model we could study the effect of the combination treatment in 
vivo and evaluate the effect of systemic delivery of AZA+RA could effect tumor progression. 
We performed two types of xenografts with three different 1p36- cell lines. In the first one 
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(SK-N-AS) we injected the cells (D0) and started treatment with AZA+RA on D1 (looking at 
tumor development), which resulted in no difference between the Ctrl (DMSO) and RA 
(only) cohort. The AZA (only) cohort showed a reduction in tumor growth, and the AZA+RA 
group showed the biggest difference with tumors four times smaller than the Ctrl group. To 
evaluate the effect on already formed tumors (tumor progression), we injected cells (LAN-1 
and CHP-212) and let the tumors grow for 8 days, to a size around 200mm3, at which point 
we started treatment. Resulting in abolished tumor growth in both cell lines after the start of 
the combined (AZA+RA) treatment.  
To investigate the long term effect of the combined treatment we treated the cells in vitro 
with AZA+RA for 10 days after which we terminated the treatment. Even after termination of 
treatment the cells maintained a pronounced neuronal morphology for at least 18 more days 
and showed no signs of reentering the cell cycle. In vivo we treated mice for 15 days (D8-
D22) after which we terminated the treatment and followed the tumor growth. The tumors did 
eventually grow to the experimental endpoint (EP) of 1000mm3, but with an almost doubling 
for survival 54 days compared to Ctrl (22 days). Showing that the combined treatment with 
AZA+RA prolongs survival even when the tumor is not removed and the treatment is 
terminated.  
By combining RNA sequencing together with methylation analysis of xenografted tumors at 
the experimental endpoint of LAN-1 and SK-N-AS tumors, we could get an insight into how 
the methylome changed after treatment and what the genetic impact was in terms of gene 
expression. To establish the demethylation effect we performed a bisulfate conversion 
followed by a genomewide methylation analysis using Infinimum Human Methylation 450 
BeadChip array. Unsupervised clustering of differentially methylated points (within 2kb from 
the transcription startsite (TSS)) showed a clear grouping of tumors treated without AZA 
(Ctrl or RA alone) and tumors treated with AZA (AZA alone or AZA+RA) and a significant 
reduction in methylation levels all throughout the genome.  
When looking at the expressional changes in the different treatment groups we found very 
limited effect in the RA (only) treated group. In SK-N-AS a substantial number of genes were 
differentially regulated in the AZA and AZA+RA groups. However, in the LAN-1 tumors 
only the combined treatment had a substantial effect on gene expression. Indicating that at 
least in the LAN-1 cell demethylation alone is not enough to induce expression of suppressed 
genes. It seems that is not enough to just remove the break, there is a need for some 
accelerator to get the wheels rolling. The correlation between increased gene expression in 
genes with demethylated promoters showed weak to no correlation.  
Gene ontology (GO) analysis of the treated xenografted tumors at EP when tumors reached 
1000mm3 showed that the MYCN amplified tumors (LAN-1 and CHP-212) showed a 
response characterized by neuronal differentiation terms while the non-MYN amplified cell 
line (SK-N-AS) showed categories involving immune response and cell death. Indicating that 
the cellular response may vary depending on cell type, but that the decreased tumor growth 
may still occur in tumors with different genetic background.  
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When looking at the gene list of differentially expressed genes from EP we could not find 
clear driver genes that we could conclude to be driving the response to AZA+RA. Instead we 
decided to look earlier when the changes between the treatment groups actually occur. We 
repeated the xenograft experiment with the LAN-1 cells and decided to harvest half of the 
tumors at D10 (after 48h of treatment) and the other half at day 14 (six days after treatment). 
The discovery that there was a decrease in mitotic cells already at D10 when we were still 
unable to see a difference between the groups in the growth curve, indicated that we were on 
the right track.  
RNA sequencing of the tumors showed a moderate change in gene expression at D10, but a 
larger change at D14. Unexpectedly, the top hit in the gene set enrichment assay (GSEA) 
showed “hypoxia”. The key regulators of hypoxia are the hypoxia inducible factors (HIFs) 
shown to increase cell survival and activate hypoxia response elements (HRE). Hypoxia 
inducible factor 2 alpha (HIF2α) encoded by the gene Endothelial PAS domain-containing 
protein 1 (EPAS1), was induced by the combined treatment. Contrary to our experiment 
several studies have suggested EPAS1 as a neuroblastoma oncogene and have reported high 
levels of EPAS1 in high-risk NB [131-134]. 
HIF´s has been shown to be regulated at a protein level by proteosomal degradation and 
hypoxia induced stabilization. Western blot at D10 and D14 was performed showing an 
moderate elevated amount of HIF2α already at D10. This results show that the protein 
regulation precedes the transcriptional response shown at D14. Expression levels of HIF1α 
after AZA+ RA treatment remained unchanged. To understand if induction of EPAS1/HIF2α 
is dependent on decreased oxygen levels in the tumors; we decided to treat NB cell in vitro in 
normoxia (21% O2) or in hypoxia (1% O2) with AZA+RA. Western blot results show that in 
contrast to Ctrl, AZA+RA in normoxic conditions upregulate HIF2α equivalent to the levels 
expressed in hypoxic conditions. Confirming that the response is due to treatment of 
AZA+RA and not solely dependent on the oxygen level.   
To understand the transcriptional changes over time we plotted expression of hypoxia, cell 
cycle and neuronal genes at our different time points. Compared to untreated cells grown in 
normoxia there was a clear increase of hypoxia genes in both Ctrl and AZA+RA treated 
tumors at D10. At D14 there was a significantly higher expression in the AZA+RA tumors 
compared to Ctrl. At EP the levels of hypoxia genes had decreasing compared to D10, 
although the tumors were larger, indicating that it might not be oxygen level dependent. Cell 
cycle genes were significantly lesser expressed in AZA+RA tumors at D14 and EP. 
Expression of genes associated with neuronal differentiation was slightly increases at D14 
and was substantially increased at EP. Concluding that the cells in the AZA+RA group, 
increase the response to hypoxia at the same time as the cell cycling genes decrease, later 
leading to an induction of neuronal genes. The first response to the treatment is hypoxia and 
reduced proliferation, and later neuronal differentiation.  
When examining the methylation changes of the promoter of EPAS1 a significant but minor 
change in methylation status could be confirmed. Questioning whether the demethylation is 
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responsible for the increased expression. Although, we cannot rule out that demethylation of 
the promoter may have occurred earlier, but has then been methylated again. 
To understand if the increased EPAS1 expression after AZA+RA treatment is important for 
the growth inhibition of the tumors, we decided to perform a loss-of-function experiment. In 
which we treated the xenografted mice with HIF2α inhibitor PT2385. PT2385 is a small 
molecule designed to block the interaction between HIF2α and its dimerization partner 
ARNT, thereby preventing the hypoxia induced stabilization, subsequently preventing the 
activation of HIF2a target genes and leaving the protein for degradation. 
Immunoprecipitation was used to confirm the disruption between HIF2α and ARNT. The 
experiment resulted in a reduction in the anti-tumoral effect of combined therapy in 
neuroblastoma cells. Tumors treated with AZA+RA+PT2385 lost their responsiveness to the 
AZA+RA treatment and continued growth in the same pace as the Ctrl group. Indicating that 
the effect is at least partly dependent on the increase in HIF2α levels. Interestingly, the 
tumors in the PT2385 (only) group showed an increased growth compared to Ctrl, exhibiting 
a significant difference at D14 and continued to be larger at EP, however not significantly.  
To determine if the genes regulated by the AZA+RA treatment at D14 could be of a clinically 
predictive value, we utilized a data set of 498 (SEQC) RNA sequenced NB tumors. Genes 
being significantly upregulated respectively down regulated at least 2-fold after AZA+RA 
treatment were clustered using a k-mean analysis. Tumors in the cluster expressing up-
regulated genes selected from the RNA sequencing showed a better overall survival (OS), as 
well as lower INSS stage and fewer MYCN amplified tumors. The opposite was shown for 
the cluster tumors selected by genes down-regulated after AZA+RA treatment.  
To clarify the role of EPAS1 in NB, as our data contradicted previously published data on 
EPAS1. We plotted EPAS1 level in the SEQC data (498 sequenced NB tumors) as well as a 
database (KOCAK) containing 649 microarrayed NB tumors. We found a clear correlation 
between EPAS1 expression and high event free survival, overall survival (OS), lower risk 
and tumor grade/stage. The opposite was true when we plotted for HIF1α, indicating that the 
two hypoxia inducible factors could have opposite functions. Using one of the stronger 
markers of aggressive NB we could see a negative correlation between MYCN amplified 
tumors and EPAS1expression and a positive correlation with HIF1α. We also looked at 
protein levels of HIF2α in NB tumors samples and found that 6 out of 8 of the low grade 
samples (stage 1-3) expressed high levels HIF2α, and in stage 4 only 1 out of 9 samples 
expressed HIF2α.  
Our study suggests that HIF2α may act as a tumor suppressor in NB, potentially due to its 
capacity to promote neuronal differentiation. Previous studies indicating the HIF2α could be 
a NB oncogenes were majorly performed using immunohistochemistry as well as with a 
small number (n=88) of NB arrayed tumors, potentially explaining the differences in our 
study.  
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3.2   PAPER  II.    
The work presented in Paper I showed an upregulation of EPAS1 after combined treatment 
with the epigenetic drug AZA and the neuronal differentiation promoting drug RA. We 
revealed a correlation between expression of the hypoxia inducing factor HIF2α as the tumor 
growth is impeded and neuronal differentiation induced. Correlating the upregulation of 
EPAS1 with better survival and neuronal differentiation in neuroblastoma. However, the role 
of EPAS1/HIF2α tumor biology appears context dependent and several reports has classified 
HIF2α as an oncogene or as a tumor suppressor in different types of cancer.  Additionally, it 
has been suggesting that recently developed small molecule antagonist specific for HIF2α 
could be used as a treatment for children with neuroblastoma. 
In this article (Paper II) we continued exploring the role of EPAS1/HIF2α in neuroblastoma. 
To establish if expression of EPAS1 correlates with clinical outcome we decided to start by 
comparing several datasets of neuroblastoma tumors. Surprisingly, analysis showed that three 
(n=102, 249 and 88) out of the six available datasets used showed a correlation between high 
expression levels of EPAS1 and worse survival, although only one of which was significant. 
Upon closer inspection, we found that the studies contained an uneven distribution of 
neuroblastoma tumors. One (n=102) study only contained non-MYCN amp tumors, another 
(n=249) was biased by the vast majority of tumors being grade IV. Implying that an analysis 
using these datasets would be less suitable for making conclusions of clinical value. 
When looking at the remaining three datasets they all had an even distribution of tumors of 
all stages, a greater number of tumors (n=498, 649 and 251) and were not biased toward a 
certain genetic alteration. Analysis showed a clear significant correlation between high levels 
of EPAS1 and better overall survival (OS). Additionally, one of the studies were RNA-
sequence based instead of array-based like the rest. Neuroblastoma tumors with high 
expression of EPAS1 have better patient outcomes and are classified as lower grade, 
indicating that EPAS1 may have tumor suppressive properties in neuroblastoma. 
To further illuminate the role of EPAS1 we looked at genes involved in neuronal 
differentiation, proliferation and genes with oncogenic properties already proven in 
neuroblastoma. When comparing the gene expression of EPAS1 to these groups of genes, we 
found a correlation with differentiation associated genes which also correlates with better 
outcome. Additionally, there was an inverted correlation with proliferation and telomere 
maintenance genes, which in turn was correlated with worse survival for neuroblastoma 
patients. We therefore speculate that EPAS1 may have a role in the neuronal differentiation 
process during development.  
To test the HIF2α antagonist as a potential treatment in neuroblastoma; we grew a panel of 
neuroblastoma cell lines of varying genetic status in the presents of either HIF2α antagonist 
#2 or PT2385 at different concentrations.  Interestingly we found that in our 1p36+ cell line 
SK-N-SH there was a small but significant decrease in proliferation in the presence of either 
inhibitor. On the contrary, in all of the 1p36- cell lines, which are classified as more 
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aggressive, treatment with one or both of HIF2α inhibitor resulted in an increased 
proliferation. Complementary we tested the treatment in LAN-1 cells grown in hypoxic 
conditions and found no effect of the inhibitor.  
To investigate the effect of an HIF2α inhibitor in an animal model, we decided to use a 
xenograft mouse model and proceeded by injecting three of the aggressive cell lines 
subcutaneously in nude mice. The mice were treating daily with the inhibitor PT2385 and 
resulted in no significant difference in tumor growth between the treatment groups. Although 
further experiments are required to verify the clinical effect of a HIF2α inhibitor in 
neuroblastoma, our results indicated that treatment with the HIF2α inhibitor would not be 
beneficial for patients with neuroblastoma.  
To understand a possible role of HIF2α/EPAS1 during embryonic development we utilized 
data from a single cell study of the sympathoadrenal lineage in the developing adrenal gland 
in mice performed by the Adameyko lab [34]. We utilized the single cell data to study in 
which cell populations Epas1 was expressed. We found the Epas1 expression patterns 
coincided with the more differentiated cells belonging the chromaffin group. Additionally, we 
looked at the consensus genes of Epas1 which in a GO analysis showed a strong 
neuron/norepinephrine association. This data confirmed our hypothesis that EPAS1 may play 
a role in the differentiation process or atleast is correlated with characteristics of more mature 
cells.  
Finally, to evaluate if EPAS1 and associated genes during development can be of predictive 
value for clinical outcome in neuroblastoma patients, we went back to the 498 sequenced 
neuroblastoma tumors. Utilizing the top 100 genes associated with EPAS1 expression from 
the single cell data, we could perform a k-means analysis. Resulting in two clusters of 
tumors, with 58 genes positively associated with EPAS1 and 10 with an inverse correlation. 
The first cluster with high expression levels of EPAS1 associated genes were classified as 
low-risk, with better overall survival and MYCN non-amplified tumors. Were as the opposite 
was seen in the cluster of tumors with an inverse expression patters of the EPAS1 associated 
genes.   
In summary, in paper II we show a correlation between high expression of EPAS1 in 
neuroblastoma tumors and better OS survival, lower grade tumors and non-MYCN-amplified 
tumors. However, we cannot formally exclude the possibility that EPAS1/HIF2α might be 
involved in processes contributing to more malignant neuroblastoma. Judging from the 
results in this study EPAS1 cannot be classified as a neuroblastoma oncogene, but might 
instead be associated with a tumors suppressive role and may also carry a predictive value of 
clinical outcome in NB. 
 
   
  23 
3.3   PAPER  III.  
Limiting number of mutations in neuroblastoma and the need for new therapeutic strategies 
are leading scientists to explore alternative mechanisms underlying the pathogenesis of 
neuroblastoma. In this study (Paper III) have we used bioinformatic tools to study fusion 
proteins. Other cancers have shown to have fusion proteins as oncogenic drivers [137, 149]. 
Using FusionCatcher [150], we analyzed a dataset of 172 paired-end RNA sequenced NB 
tumors (NB172). Containing 139 high risk, 19 intermediate and 14 low risk neuroblastoma 
tumors. We found fusions in 163 out of the 172 tumors, with an average of 38 fusions per 
sample, which is more that the average of mutations found in NB tumors. Additionally, 103 
fusions occurred at a frequency higher than 10%. The majority of fusions (786/924) were 
intrachromosomal fusions. The fusion proteins resulted in truncated proteins, bona fide fusion 
proteins to deletions of genes. Fusion proteins are capable of generating new gene products 
with oncogenic potential. Allowing for new unexplored therapeutic targets.  
Several of the fusions were enriched in chromosomes which are altered in NB pathology. By 
looking at fusions in the different risk groups, we found that fusions in the high-risk NB were 
located on chromosome 17 and 22, while in the low-risk tumors the fusions were enriched on 
chromosome 11q. Looking at NB statistics aggressive NB gain of 17q is a marker for more 
aggressive NB [16] while chromosome 22 alterations are associated with metastatic and 
aggressive tumors [151]. Several of the fusions transcripts comprised of already proven 
oncogenic genes in NB, such as MYCN, BRCA1, LMO1 and TERT. 
To validate the fusion transcripts found in the NB172 data set, we decided to perform our 
own paired-end RNA sequencing (14 NB tumors + eight NB cell lines) in which we 
identified 139 fusions out of with 82 (59%) were present in the NB172 tumors. To determine 
the NB specificity of the fusions, we compared the samples to a dataset containing 161 
sequenced healthy human adrenal glands and found very little over lap (6% in the NB172 and 
3% on our validation cohort). Comparing our date to another pediatric cancer; rhabdoid 
cancer where we found more than double the amount of fusions (2055). However, the overlap 
between the to childhood cancers were only 2%, indicating that the fusions identified are NB 
specific. Interestingly, contrary to the NB fusions the majority of the fusions found in 
rhabdoid tumors were interchromosomal fusions. 
To validate the fusions, we designed primers spanning the fusion point in selected fusions. 
Using RT-PCR we analyzed the the chimeric transcript of six different fusions in a panel of 
ten NB tumor samples, seven NB cell lines and 14 human tissues. Showing that the fusions 
(5/6) were expressed in an NB specific manner.  
One of the top 25 most recurrent fusions in NB is the ZNF415-BAG2 fusion (∆BAG2), 
which is present in 31 out of the 172 sequenced NB tumors (18%). BCL2 associated 
athanogene (BAG2) is a co-chaperone involved in the degradation of miss-folded proteins in 
an ubiquitin independent manner. BAG2 has also been shown to increase differentiating NB 
cells and clears phosphorylated TAU from neuronal microtubule, helping to maintain the 
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stabilization of axons in neurons [152]. Looking at the sequence of ∆BAG2, we could see 
that this fusion results in a truncated version of BAG2 lacking exon1. When looking at 
different animal species we found that the truncated part contains a highly conserved N-
terminal coiled-coil domain. To understand the role of ∆BAG2 in NB and if it is of clinical 
significance, we looked at the genes differentially expressed in NB containing ∆BAG2. We 
found 32 genes with a significantly elevated expression and 34 genes with a decreased 
expression, which we used in the 498SEQC. The upregulated genes were correlated with 
high-risk NB, and the inverted correlation with the downregulated genes.  
Looking at protein level in a panel of 13 NB tumors and six adrenal glands, blotting for 
BAG2 showed that the wtBAG2 was expressed in all samples, including both tumors and 
adrenal glands, however, five of the NB tumors co-expressed ∆BAG2 and none in normal 
adrenalglands. As BAG2 has been shown to be important for the clearance of phosphorylated 
TAU (pTAU) [152] and when blotting for TAU we could see that the tumors expressing 
∆BAG2 had a much higher expression of pTAU. To validate that this is due to the presence 
of ∆BAG2, we overexpressed ∆BAG2 in an NB cell line (SK-N-FI) and could clearly show 
that when ∆BAG2 is over expressed the levels of pTAU increase. Overexpression of wt 
BAG2 showed a reduction in pTAU and co-expression or wtBAG2 and ∆BAG2 showed that 
wtBAG2 was unable to clear pTAU, implying a dominant negative relationship with ∆BAG2. 
BAG2 has been shown to bind to heat shock cognate 70 (HSC70) [153] immunoprecipitation 
experiment showed that wt BAG2 binds HSC70 but ∆BAG2 does not. Additionally, 
treatment of SK-N-FI cells with/without overexpression of wtBAG2 or ∆BAG2 showed that 
cells overexpressing ∆BAG2 showed a weaker response to Retinoic acid (RA) with less 
neurite formation.  
The recurrence of fusion transcripts expressed in a NB specific matter, together with the 
identification of fusions in already known NB oncogenes, implies that several of the fusion 
transcripts may have oncogenic properties contributing to the NB pathogenesis. Thus these 
fusion transcripts could constitute a source of altered transcripts, distinct from DNA-altering 
mutations, potentially promoting neuroblastoma.    
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4   DISCUSSION  
The role of HIF2α in cancer still remains unclear: is HIF2α a tumor suppressor or an 
oncogene? Many scientific studies report different roles in different types of cancer, 
suggesting that the role of HIF2α is context dependent. There has even been contradicting 
results within the same cancer type, like in glioma [129, 130]. A possibility is that the role of 
HIF2α in cancer is depending on the cell or origin. In paper I we had the opportunity to 
analyze EPAS1 expression in glioma, a cancer type that have both a pediatric version and an 
adult version of the pathogenesis. When we plotted EPAS1 expression compared to overall 
survival (Paper I, S6 A and C), we found a very interesting discovery. In pediatric glioma, 
high EPAS1 expression is associated with better prognosis and overall survival. While in 
adult glioma the opposite is true. In adult glioma high EPAS1 was instead associated with 
worse prognosis. The contrast between adult and pediatric glioma with regards to the 
association between high EPAS1 levels and overall survival implies that in pediatric tumors 
of the neural lineage, the role of HIF2α is different from its role in adult tumors HIF2α cancer 
dependent. In a non-pathogenic condition such as during embryonic development HIF2α 
plays a particular role when it comes to development of the CNS and heart [118, 154]. 
Additionally, in Paper II we show that in the sympathoadrenal linage EPAS1 is expressed in 
the differentiated cell chromaffin cells (Paper II, Fig4 A).  
In neuroblastoma HIF2α has mostly been suggested to be an oncogene [131-134, 155]. 
However, there are a few studies indicating a tumor suppressor effect before ours in NB 
(Paper I and II) and other cancer types [124, 125, 135, 156-159]. When looking back at some 
papers suggesting an oncogenic role for HIF2α, there are some limiting factor in those 
studies such as the small number of sequenced/arrayed tumors and the fact that 
immunohistchemical stainings of NB tumors are used to validate the expression of HIF2α. 
Unfortunately the reliability of HIF2α antibodies are limited, due to the potential 
unspecificity. In a western blot, however, it is easier to determine the correct band if you use 
a control or by looking at the ladder. We believe that using a larger set of NB tumors, which 
is evenly distributed with regards to clinical parameters such as MYCN status and NB 
staging, will give a more reliable answer to the predicament of the role of EPAS1 in NB.  
Simon et al show an association between high levels of HIF1α in MYCN-amp tumors, and 
high levels of HIF2α in non-MYCN amp tumors [135]. Recently even the group that has 
published the majority of the papers on HIF2α as an oncogenes in NB, published a paper 
[160] in which they show that EPAS1 is highly expressed in non-MYCN amplified tumors 
(Fig 2E), however still argue in the paper that HIF2α is oncogenic. Although, it is hard to 
fully exclude an oncogenic role of HIF2α, however it can be concluded that HIF2α isn’t a 
permanent feature of high-risk NB.  
In paper I we saw a week correlation between de methylation of the promoter region and 
gene expression. Showing that AZA treatment alone is not enough to activate gene 
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expression, indicating that the mechanisms by which AZA re-sensitize the NB cells to RA 
might not be due to demethylation alone. Implying that there might be off-target effects. 
Previous studies has shown that AZA can induce reactive oxygen species (ROS) [161] and 
DNA damage [162]. However, this was not seen in the tumors treated with AZA+RA, instead 
they showed a reduction in the response to oxidative phosphorylation and DNA repair (Paper 
I, Fig 3G).  
Our NB cell lines show varying genetic changes SK-N-AS is 1p36-, MYCN wt and p53 
mutation, CHP-212 is 1p36-, MYCN amplified and p53 wt and LAN-1 is 1p36-, MYCN 
amplified and P53 null mutated. Both SK-N-AS and LAN-1 with mutation on P53 exhibit 
increased apoptosis upon AZA+RA treatment, indicating that the apoptotic response in 
independent of a normal p53. 
Both RA and AZA are FDA approved drugs which are already used for treatment of different 
cancers types. AZA (decitabine) is used to treat myelodysplasive syndrome [163]. RA 
(tretinoin and isotretinoin) is used in high-risk NB after myeloablastive chemotherapy, total 
body irradiation and transplanted autologous bone marrow [29, 146]. There are clinical trails 
using the combination of AZA+RA to treat acute myeloid leukemia [164, 165]. PT2385 is 
suggested for clinical trail in different cancer where HIF2α has shown oncogenic properties  
[108, 166-168] 
Many studies start treatment of their xenograft experiments at D1 (the day after cell 
transplantation), we believe that it is important to let the tumors establish before the treatment 
start, for the study to be relevant in a clinical perspective. When a patient is diagnosed a 
tumor has already formed and it is there for of uttermost importance to treat a formed tumor 
instead of during tumor development. There is a great difference in studying tumor formation 
or establishment compared to studying the effect of a treatment on an already formed tumors. 
The xenograft model we used in our study is a good model to study the effect of systemic 
delivery of a drug on tumor growth. However, there are limitations when using this 
subcutaneous xenograft model, as the tumors is located in a different organ and therefor 
environmental factors may influence the results as well as no proper metastasis formation. 
Another approach that could be beneficial is orthotopic xenografts, where the NB cells 
instead are injected in the renal capsule [169]. 
Pediatric neuroblastoma remains a therapeutic challenge and there is a need for new treatment 
strategies. The low mutation load and the incomplete understanding of what dives 
neuroblastoma pathogenesis restricts the potential therapeutic targets. In this thesis I have 
focused on investigating alternative mechanisms such as DNA methylation of promoters of 
putative tumor suppressors or fusion transcripts and proteins in the quest to further the 
understanding of neuroblastoma biology and find new potential therapeutic targets. 
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